Hong Kong Tightens Medical Aesthetic Injection Rules Starting March 2026
HK01 · 1 SOURCESabout 3 hours ago3 MIN
Summary
The Department of Health announced on Monday that the Committee on the Regulation of Private Healthcare Institutions has approved updated standards requiring all injection and infusion products used in licensed private medical institutions to fall within three approved categories: registered pharmaceutical products under the Pharmacy and Poisons Regulations, compliant human organ or tissue products under the Human Organ Transplant Ordinance, or medical devices listed under MDACS. The regulatory changes target the booming medical aesthetic industry, with over 3,400 clinic licenses or small practice exemptions currently in effect as of September 21. The implementation will occur in two phases, with the new Code of Practice taking effect one month after gazettal and the requirement for MDACS-listed injectable medical devices taking effect March 1, 2026. Health authorities are urging private medical institutions to verify product compliance with suppliers immediately to ensure a smooth transition.
Key Points
- The Committee on the Regulation of Private Healthcare Institutions has approved updated regulations requiring all injection and infusion products in licensed private medical institutions to be registered pharmaceutical products, compliant human tissue products, or listed medical devices
- Department of Health plans to gazette Code of Practice amendments in Q4 this year, with the new rules taking effect one month after publication
- Starting March 1, 2026, all injectable medical devices including hyaluronic acid fillers must be listed under MDACS
- As of September 21, the Department of Health has issued over 3,400 clinic licenses or small practice exemptions to facilities offering medical services
- Products containing botulinum toxin are classified as Schedule 1 poisons and prescription drugs, requiring prescription by local registered doctors or dispensing by registered pharmacists under supervision
Why It Matters
The new regulatory framework addresses longstanding concerns about safety standards in Hong Kong's rapidly growing medical aesthetic sector. By mandating that injectable products like hyaluronic acid and skin fillers meet MDACS listing requirements, the government aims to protect consumers from unregulated or substandard products that could cause serious harm. This move aligns Hong Kong's regulatory standards with international best practices, potentially restoring confidence in the city's medical aesthetic industry following high-profile safety incidents in recent years.
The new regulatory framework addresses longstanding concerns about safety standards in Hong Kong's rapidly growing medical aesthetic sector. By mandating that injectable products like hyaluronic acid and skin fillers meet MDACS listing requirements, the government aims to protect consumers from unregulated or substandard products that could cause serious harm. This move aligns Hong Kong's regulatory standards with international best practices, potentially restoring confidence in the city's medical aesthetic industry following high-profile safety incidents in recent years.